Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist

G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, P. G. Crosignani

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. Methods: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of ≥14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. Results: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P <0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B. Conclusion: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.

Original languageEnglish
Pages (from-to)2258-2262
Number of pages5
JournalHuman Reproduction
Volume16
Issue number11
Publication statusPublished - 2001

Fingerprint

Hormone Antagonists
Luteal Phase
Gonadotropins
Gonadotropin-Releasing Hormone
Progesterone
Insemination
Chorionic Gonadotropin
Corpus Luteum Hormones
Estradiol
Follicular Phase
Corpus Luteum
Pregnancy
Therapeutics
Serum

Keywords

  • GnRH antagonist
  • Infertility
  • Intrauterine insemination
  • Luteal phase

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Ragni, G., Vegetti, W., Baroni, E., Colombo, M., Arnoldi, M., Lombroso, G., & Crosignani, P. G. (2001). Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Human Reproduction, 16(11), 2258-2262.

Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. / Ragni, G.; Vegetti, W.; Baroni, E.; Colombo, M.; Arnoldi, M.; Lombroso, G.; Crosignani, P. G.

In: Human Reproduction, Vol. 16, No. 11, 2001, p. 2258-2262.

Research output: Contribution to journalArticle

Ragni, G, Vegetti, W, Baroni, E, Colombo, M, Arnoldi, M, Lombroso, G & Crosignani, PG 2001, 'Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist', Human Reproduction, vol. 16, no. 11, pp. 2258-2262.
Ragni, G. ; Vegetti, W. ; Baroni, E. ; Colombo, M. ; Arnoldi, M. ; Lombroso, G. ; Crosignani, P. G. / Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. In: Human Reproduction. 2001 ; Vol. 16, No. 11. pp. 2258-2262.
@article{bc95d7cce9154fb6b482fcba2eb6d9a5,
title = "Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist",
abstract = "Background: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. Methods: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of ≥14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. Results: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P <0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3{\%} per patient and 12.2{\%} per cycle), equally distributed in group A and in group B. Conclusion: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.",
keywords = "GnRH antagonist, Infertility, Intrauterine insemination, Luteal phase",
author = "G. Ragni and W. Vegetti and E. Baroni and M. Colombo and M. Arnoldi and G. Lombroso and Crosignani, {P. G.}",
year = "2001",
language = "English",
volume = "16",
pages = "2258--2262",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist

AU - Ragni, G.

AU - Vegetti, W.

AU - Baroni, E.

AU - Colombo, M.

AU - Arnoldi, M.

AU - Lombroso, G.

AU - Crosignani, P. G.

PY - 2001

Y1 - 2001

N2 - Background: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. Methods: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of ≥14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. Results: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P <0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B. Conclusion: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.

AB - Background: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. Methods: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of ≥14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. Results: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P <0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B. Conclusion: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.

KW - GnRH antagonist

KW - Infertility

KW - Intrauterine insemination

KW - Luteal phase

UR - http://www.scopus.com/inward/record.url?scp=0035149153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035149153&partnerID=8YFLogxK

M3 - Article

C2 - 11679500

AN - SCOPUS:0035149153

VL - 16

SP - 2258

EP - 2262

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 11

ER -